Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Sep. 30, 2020 | Nov. 13, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | GB SCIENCES INC | |
Entity Central Index Key | 0001165320 | |
Current Fiscal Year End Date | --03-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 281,779,436 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2020 | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2020 | Mar. 31, 2020 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 545,020 | $ 2,406 |
Prepaid expenses and other current assets | 18,776 | 18,776 |
Note receivable | 4,350,000 | 5,224,423 |
Current assets from discontinued operations | 1,997,037 | 1,755,275 |
TOTAL CURRENT ASSETS | 6,910,833 | 7,000,880 |
Property and equipment, net | 31,278 | 37,821 |
Intangible assets, net of accumulated amortization of $17,611 and $12,287 at September 30, 2020 and March 31, 2020, respectively | 1,545,355 | 1,128,702 |
Long term assets from discontinued operations | 5,766,598 | 6,185,465 |
TOTAL ASSETS | 14,254,064 | 14,352,868 |
CURRENT LIABILITIES: | ||
Accounts payable | 2,346,652 | 1,913,049 |
Accrued interest | 479,255 | 366,865 |
Accrued liabilities | 1,205,248 | 813,618 |
Notes and convertible notes payable and line of credit, net of unamortized discount of $9,624 and $608,580 at September 30, 2020 and March 31, 2020, respectively | 6,428,278 | 5,054,728 |
Indebtedness to related parties | 710,075 | 586,512 |
Note payable to related party | 151,923 | |
Income tax payable | 620,856 | 592,982 |
Current liabilities from discontinued operations | 1,348,111 | 1,406,080 |
TOTAL CURRENT LIABILITIES | 13,138,475 | 10,885,757 |
Long term liabilities from discontinued operations | 3,465,160 | 3,555,605 |
TOTAL LIABILITIES | 16,603,635 | 14,441,362 |
Commitments and contingencies (Note 8) | ||
STOCKHOLDERS' DEFICIT: | ||
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 280,532,686 and 275,541,602 outstanding at September 30, 2020 and March 31, 2020, respectively | 28,054 | 27,554 |
Additional paid-in capital | 97,679,001 | 97,271,157 |
Accumulated deficit | (100,056,626) | (97,387,205) |
TOTAL STOCKHOLDERS' DEFICIT | (2,349,571) | (88,494) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 14,254,064 | $ 14,352,868 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) | Sep. 30, 2020 | Mar. 31, 2020 |
Intangible assets, accumulated amortization | $ 17,611 | $ 12,287 |
Notes and convertible notes payable, unamortized discount, current | $ 9,624 | $ 608,580 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 280,532,686 | 275,541,602 |
Common stock, shares outstanding (in shares) | 280,532,686 | 275,541,602 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Sales revenue | ||||
Cost of goods sold | ||||
Gross profit | ||||
General and administrative expenses | 491,818 | 1,291,232 | 1,007,071 | 3,082,697 |
LOSS FROM OPERATIONS | (491,818) | (1,291,232) | (1,007,071) | (3,082,697) |
OTHER INCOME/(EXPENSE) | ||||
Interest expense | (410,946) | (352,736) | (1,082,874) | (664,937) |
Debt default penalty | (286,059) | |||
Other income/(expense) | (1,750) | 92,707 | (3,374) | 92,707 |
Total other expense | (412,696) | (260,029) | (1,372,307) | (572,230) |
LOSS BEFORE INCOME TAXES | (904,514) | (1,551,261) | (2,379,378) | (3,654,927) |
Income tax benefit/(expense) | (19,034) | 57,392 | (27,874) | |
LOSS FROM CONTINUING OPERATIONS | (923,548) | (1,493,869) | (2,407,252) | (3,654,927) |
Gain/(loss) from discontinued operations | 118,090 | (1,434,737) | (244,906) | (1,812,563) |
NET LOSS | (805,458) | (2,928,606) | (2,652,158) | (5,467,490) |
Net loss attributable to non-controlling interest | (245,565) | (377,781) | ||
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC. | (805,458) | (2,683,041) | (2,652,158) | (5,089,709) |
Continuing operations | (923,548) | (1,493,869) | (2,407,252) | (3,654,927) |
Discontinued operations | 118,090 | (1,189,172) | (244,906) | (1,434,782) |
Net loss | $ (805,458) | $ (2,683,041) | $ (2,652,158) | $ (5,089,709) |
Continuing operations (in dollars per share) | $ 0 | $ (0.01) | $ (0.01) | $ (0.01) |
Discontinued operations (in dollars per share) | 0 | 0 | 0 | (0.01) |
Net loss (in dollars per share) | $ 0 | $ (0.01) | $ (0.01) | $ (0.02) |
Weighted average common shares outstanding - basic and diluted (in shares) | 280,532,686 | 252,700,538 | 279,257,607 | 248,392,203 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Cash Flows (Unaudited) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Mar. 31, 2020USD ($) | |
OPERATING ACTIVITIES: | |||||
Net loss | $ (805,458) | $ (2,928,606) | $ (2,652,158) | $ (5,467,490) | |
Loss from discontinued operations | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Net loss from continuing operations | (2,407,252) | (3,654,927) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||
Depreciation and amortization | 15,612 | 76,716 | |||
Stock-based compensation | 341,724 | ||||
Amortization of debt discount and beneficial conversion feature | 748,956 | 434,750 | |||
Interest expense on conversion of notes payable | 26,804 | ||||
Loss on extinguishment | 124,158 | ||||
Default penalty on convertible note payable | 286,059 | ||||
Changes in operating assets and liabilities: | |||||
Prepaid expenses and other current assets | 180,060 | ||||
Accounts payable | 262,881 | 304,550 | |||
Accrued expenses | 414,130 | 187,133 | |||
Accrued interest | 325,925 | 190,695 | |||
Income tax payable | 27,874 | ||||
Indebtedness to related parties | 123,563 | ||||
Net cash used in operating activities of continuing operations | (202,252) | (1,788,337) | |||
Net cash used in operating activities of discontinued operations | (10,602) | (1,758,120) | |||
Net cash used in operating activities | (212,854) | (3,546,457) | |||
INVESTING ACTIVITIES: | |||||
Proceeds from note receivable | 701,923 | ||||
Acquisition of intangible assets | (91,862) | ||||
Net cash provided/(used) in investing activities of continuing operations | 701,923 | (91,862) | |||
Net cash used in investing activities of discontinued operations | (104,265) | (462,920) | |||
Net cash provided/(used) in investing activities | 597,658 | (554,782) | |||
FINANCING ACTIVITIES: | |||||
Proceeds from issuance of common stock | 550,225 | ||||
Gross proceeds from warrant exercises | 151,202 | 944,975 | |||
Gross proceeds from convertible notes payable | 150,000 | 2,600,000 | |||
Proceeds from Line of Credit | 125,000 | ||||
Principal payment on note payable to related party | (151,923) | ||||
Fees for issuance of convertible note | (175,000) | ||||
Brokerage fees for issuance of common stock and warrants | (15,121) | (166,027) | |||
Net cash provided by financing activities of continuing operations | 259,158 | 3,754,173 | |||
Net cash provided/(used) in financing activities of discontinued operations | (101,487) | 213,625 | |||
Net cash provided by financing activities | 157,671 | 3,967,798 | |||
Net change in cash and cash equivalents | 542,475 | (133,441) | |||
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 151,766 | 227,758 | $ 227,758 | ||
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 694,241 | 94,317 | 694,241 | 94,317 | $ 151,766 |
Less: cash and cash equivalents classified as discontinued operations | (149,221) | (23,639) | (149,221) | (23,639) | |
CASH AND CASH EQUIVALENTS AT END OF PERIOD FROM CONTINUING OPERATIONS | $ 545,020 | $ 70,678 | 545,020 | 70,678 | |
Cash paid for interest | 332,167 | ||||
Cash paid for income tax | |||||
Non-cash transactions: | |||||
Accrued liabilities forgiven in connection with Wellcana Note letter agreement | 172,500 | ||||
Depreciation capitalized in inventory | 272,267 | 273,090 | |||
Accrued interest capitalized in convertible note principal | 223,094 | ||||
Property capitalized under operating leases | 182,624 | ||||
Patent acquisition costs capitalized in intangible assets | 320,722 | 67,008 | |||
Stock options issued to acquire intangible assets | 105,000 | ||||
Stock issued upon conversion of notes payable | 280,000 | ||||
Induced dividend from warrant exercises | 17,263 | 230,025 | |||
Cumulative effect of the new lease standard | 7,550 | ||||
Convertible Notes Payable [Member] | |||||
Non-cash transactions: | |||||
Beneficial conversion feature on notes payable | $ 150,000 | $ 133,806 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) | Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Mar. 31, 2019 | 240,627,102 | |||||||||
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019 | $ (7,550) | $ (7,550) | ||||||||
Balance at Mar. 31, 2019 | $ 24,063 | $ 93,020,015 | $ (84,743,836) | $ 8,855,757 | $ 17,155,999 | |||||
Net loss | (5,089,709) | (377,781) | (5,467,490) | |||||||
Issuance of stock for debt conversion (in shares) | 2,000,000 | |||||||||
Issuance of stock for debt conversion | $ 200 | 279,800 | 280,000 | |||||||
Exercise of warrants for stock (in shares) | 9,449,750 | |||||||||
Exercise of warrants for stock | $ 945 | 849,533 | 850,478 | |||||||
Share based compensation expense | 208,809 | 208,809 | ||||||||
Beneficial conversion feature on notes payable | 133,806 | 133,806 | ||||||||
Contributions from non-controlling interest | 550,001 | 550,001 | ||||||||
Compensation warrants | 132,914 | 132,914 | ||||||||
Inducement dividend from warrant exercises | 230,025 | (230,025) | ||||||||
Issuance of stock for cash, net of issuance costs (in shares) | 3,668,167 | |||||||||
Issuance of stock for cash, net of issuance costs | $ 367 | 478,329 | 478,696 | |||||||
Cancelled shares issued to consultant (in shares) | (400,000) | |||||||||
Cancelled shares issued to consultant | $ (40) | 40 | ||||||||
Balance (in shares) at Sep. 30, 2019 | 255,345,019 | |||||||||
Balance at Sep. 30, 2019 | $ 25,535 | 95,333,271 | (90,071,120) | 9,027,977 | 14,315,663 | |||||
Balance (in shares) at Jun. 30, 2019 | 246,852,769 | |||||||||
Balance at Jun. 30, 2019 | $ 24,686 | 94,095,065 | (87,232,454) | 8,723,541 | 15,610,838 | |||||
Net loss | (2,683,041) | (245,565) | (2,928,606) | |||||||
Issuance of stock for debt conversion (in shares) | 1,000,000 | |||||||||
Issuance of stock for debt conversion | $ 100 | 109,900 | 110,000 | |||||||
Exercise of warrants for stock (in shares) | 7,492,250 | |||||||||
Exercise of warrants for stock | $ 749 | 673,553 | 674,302 | |||||||
Share based compensation expense | 32,408 | 32,408 | ||||||||
Beneficial conversion feature on notes payable | 133,806 | 133,806 | ||||||||
Contributions from non-controlling interest | 550,001 | 550,001 | ||||||||
Compensation warrants | 132,914 | 132,914 | ||||||||
Inducement dividend from warrant exercises | 155,625 | (155,625) | ||||||||
Balance (in shares) at Sep. 30, 2019 | 255,345,019 | |||||||||
Balance at Sep. 30, 2019 | $ 25,535 | 95,333,271 | (90,071,120) | 9,027,977 | 14,315,663 | |||||
Balance (in shares) at Mar. 31, 2020 | 275,541,602 | |||||||||
Balance at Mar. 31, 2020 | $ 27,554 | 97,271,157 | (97,387,205) | (88,494) | ||||||
Stock options issued to acquire intangible assets | 105,000 | 105,000 | ||||||||
Net loss | (2,652,158) | (2,652,158) | ||||||||
Exercise of warrants for stock (in shares) | 4,991,084 | |||||||||
Exercise of warrants for stock | $ 500 | 135,581 | 136,081 | |||||||
Beneficial conversion feature on notes payable | 150,000 | 150,000 | ||||||||
Inducement dividend from warrant exercises | 17,263 | (17,263) | ||||||||
Balance (in shares) at Sep. 30, 2020 | 280,532,686 | |||||||||
Balance at Sep. 30, 2020 | $ 28,054 | 97,679,001 | (100,056,626) | (2,349,571) | ||||||
Balance (in shares) at Jun. 30, 2020 | 280,532,686 | |||||||||
Balance at Jun. 30, 2020 | $ 28,054 | 97,574,001 | (99,251,168) | (1,649,113) | ||||||
Stock options issued to acquire intangible assets | 105,000 | 105,000 | ||||||||
Net loss | (805,458) | (805,458) | ||||||||
Balance (in shares) at Sep. 30, 2020 | 280,532,686 | |||||||||
Balance at Sep. 30, 2020 | $ 28,054 | $ 97,679,001 | $ (100,056,626) | $ (2,349,571) |
Note 1 - Background and Signifi
Note 1 - Background and Significant Accounting Policies | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 1 GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) seeks to be a biopharmaceutical research and cannabinoid-based drug development company whose goal is to create patented formulations for safe, standardized, cannabinoid therapies that target a variety of medical conditions in both the pharmaceutical and wellness markets. The Company is engaged in the research and development of cannabinoid medicines and plans to produce cannabinoid therapies for the wellness markets based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of cannabinoid medicines with virtual operations in North America and Europe. GBSGB assets include cannabinoid medicine intellectual property, research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of conditions and several programs are in pre-clinical animal stage of development; including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes two five four one 2020, three 28 Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited balance sheets and statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified to discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11 Discontinued Operations Refer to Note 3. Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No September 30, 2020 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,637,853 158,404,020 September 30, 2020 March 31, 2020 not Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not |
Note 2 - Going Concern
Note 2 - Going Concern | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Substantial Doubt about Going Concern [Text Block] | Note 2 The Company's financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $ ( 100,056,626 September 30, 2020 ( 6,227,642 September 30, 2020 648,926 ( 3,884,877 March 31, 2020 349,195 ( 212,854 six September 30, 2020 ( 10,602 ( 3,546,457 ( 1,758,120 six September 30, 2019 Management has been able, thus far, to finance the losses through a public offering, private placements and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying financial statements do not may |
Note 3 - Discontinued Operation
Note 3 - Discontinued Operations | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | Note 3 Discontinued operations comprise those activities that were disposed of during the period or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11 There were no September 30, 2020 March 31, 2020 November 15, 2019 September 30, 2020 March 31, 2020 September 30, 2020 March 31, 2020 Continuing Nevada Subsidiaries Total Continuing Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 545,020 $ 149,221 $ 694,241 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 346,058 346,058 - 117,967 117,967 Inventory, net - 1,439,320 1,439,320 - 1,445,839 1,445,839 Prepaid and other current assets 18,776 62,438 81,214 18,776 42,109 60,885 Note receivable 4,350,000 - 4,350,000 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 4,913,796 1,997,037 6,910,833 5,245,605 1,755,275 7,000,880 Property and equipment, net 31,278 5,113,829 5,145,107 37,821 5,496,012 5,533,833 Intangible assets, net 1,545,355 571,265 2,116,620 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 81,504 81,504 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 6,490,429 $ 7,763,635 $ 14,254,064 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,346,652 $ 607,766 $ 2,954,418 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 479,255 79,123 558,378 366,865 30,787 397,652 Accrued expenses 1,205,248 48,010 1,253,258 813,618 74,394 888,012 Notes payable, net 6,428,278 485,000 6,913,278 5,054,728 480,000 5,534,728 Indebtedness to related parties 710,075 - 710,075 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable 620,856 - 620,856 592,982 - 592,982 Finance lease obligations, current - 128,212 128,212 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 11,790,364 1,348,111 13,138,475 9,479,677 1,406,080 10,885,757 Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,465,160 3,465,160 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 11,790,364 $ 4,813,271 $ 16,603,635 $ 9,479,677 $ 4,961,685 $ 14,441,362 Discontinued Operations - Revenues and Expenses The revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three six September 30, 2020 2019 For the Three Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,264,271 $ 1,264,271 $ - $ 1,548,705 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) - (2,237,779 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 - (689,074 ) (689,074 ) General and administrative expenses 491,818 81,464 573,282 1,291,232 536,814 1,828,046 INCOME/(LOSS) FROM OPERATIONS (491,818 ) 323,739 (168,079 ) (1,291,232 ) (1,225,888 ) (2,517,120 ) OTHER INCOME/(EXPENSE) Interest expense (410,946 ) (128,201 ) (539,147 ) (352,736 ) (185,599 ) (538,335 ) Other income/(expense) (1,750 ) (77,448 ) (79,198 ) 92,707 (23,250 ) 69,457 Total other expense (412,696 ) (205,649 ) (618,345 ) (260,029 ) (208,849 ) (468,878 ) INCOME/(LOSS) BEFORE INCOME TAXES (904,514 ) 118,090 (786,424 ) (1,551,261 ) (1,434,737 ) (2,985,998 ) Income tax expense (19,034 ) - (19,034 ) 57,392 - 57,392 NET INCOME/(LOSS) $ (923,548 ) $ 118,090 $ (805,458 ) $ (1,493,869 ) $ (1,434,737 ) $ (2,928,606 ) For the Six Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,815,468 $ 1,815,468 $ - $ 2,459,381 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) - (2,862,148 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 - (402,767 ) (402,767 ) General and administrative expenses 1,007,071 370,920 1,377,991 3,082,697 1,012,737 4,095,434 INCOME/(LOSS) FROM OPERATIONS (1,007,071 ) 93,685 (913,386 ) (3,082,697 ) (1,415,504 ) (4,498,201 ) OTHER INCOME/(EXPENSE) Interest expense (1,082,874 ) (261,143 ) (1,344,017 ) (664,937 ) (373,809 ) (1,038,746 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other income/(expense) (3,374 ) (77,448 ) (80,822 ) 92,707 (23,250 ) 69,457 Total other expense (1,372,307 ) (338,591 ) (1,710,898 ) (572,230 ) (397,059 ) (969,289 ) LOSS BEFORE INCOME TAXES (2,379,378 ) (244,906 ) (2,624,284 ) (3,654,927 ) (1,812,563 ) (5,467,490 ) Income tax expense (27,874 ) - (27,874 ) - - - NET LOSS $ (2,407,252 ) $ (244,906 ) $ (2,652,158 ) $ (3,654,927 ) $ (1,812,563 ) $ (5,467,490 ) Discontinued Operations - Revenues and Expenses (continued) The components of revenues and expenses associated with discontinued operations included in our condensed consolidated statements of operations for the three six September 30, 2020 2019 For the Three Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,264,271 $ 1,264,271 $ 377,007 $ 1,171,698 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) (380,629 ) (1,857,150 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 (3,622 ) (685,452 ) (689,074 ) General and administrative expenses - 81,464 81,464 424,732 112,082 536,814 INCOME/(LOSS) FROM OPERATIONS - 323,739 323,739 (428,354 ) (797,534 ) (1,225,888 ) OTHER EXPENSE Interest expense - (128,201 ) (128,201 ) (62,777 ) (122,822 ) (185,599 ) Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (205,649 ) (205,649 ) (62,777 ) (146,072 ) (208,849 ) INCOME/(LOSS) BEFORE INCOME TAXES - 118,090 118,090 (491,131 ) (943,606 ) (1,434,737 ) Income tax expense - - - - - - NET INCOME/(LOSS) $ - $ 118,090 $ 118,090 $ (491,131 ) $ (943,606 ) $ (1,434,737 ) For the Six Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,815,468 $ 1,815,468 $ 377,007 $ 2,082,374 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) (380,629 ) (2,481,519 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 (3,622 ) (399,145 ) (402,767 ) General and administrative expenses - 370,920 370,920 626,571 386,166 1,012,737 INCOME/(LOSS) FROM OPERATIONS - 93,685 93,685 (630,193 ) (785,311 ) (1,415,504 ) OTHER EXPENSE Interest expense - (261,143 ) (261,143 ) (125,372 ) (248,437 ) (373,809 ) Debt default penalty - - - - - - Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (338,591 ) (338,591 ) (125,372 ) (271,687 ) (397,059 ) LOSS BEFORE INCOME TAXES - (244,906 ) (244,906 ) (755,565 ) (1,056,998 ) (1,812,563 ) Income tax expense - - - - - - NET LOSS $ - $ (244,906 ) $ (244,906 ) $ (755,565 ) $ (1,056,998 ) $ (1,812,563 ) Discontinued Operations - Inventory Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's unaudited condensed consolidated balance sheets at September 30, 2020 March 31, 2020 September 30, 2020 March 31, 2020 Raw materials $ 2,677 $ 91,465 Work in progress 789,482 1,166,511 Finished goods 653,314 466,319 Subtotal 1,445,473 1,724,295 Allowance to reduce inventory to net realizable value (6,153 ) (278,456 ) Total inventory, net $ 1,439,320 $ 1,445,839 Discontinued Operations - Leases The Company determines if an arrangement is a lease at inception and has lease agreements for warehouses, office facilities, and equipment. These commitments have remaining non-cancelable lease terms, with lease expirations which range from 2024 2025. As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets , accrued liabilities, and operating lease obligations, long term on the unaudited condensed consolidated balance sheets. Finance leases are included in property and equipment, finance lease obligations, short term, and finance lease obligations, long term, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not All finance costs recorded in the Company's unaudited condensed consolidated financial statements for the three six September 30, 2020 2019 six September 30, 2020 $286,436, $209,086 $77,350 Operating lease costs included in continuing operations were $3,243, $1,242 $2,001 September 30, 2020, Amortization of lease assets is included in general and administrative expenses. As of September 30, 2020, no September 30, 2020 Year Ending March 31, Finance Leases 2021 (6 months) $ 266,188 2022 544,296 2023 560,625 2024 577,444 2025 594,767 Thereafter 3,781,102 Total minimum lease payments 6,324,422 Less: Amount representing interest (2,731,050 ) Present value of minimum lease payments 3,593,372 Less: Current maturities of capital lease obligations (128,212 ) Long-term capital lease obligations $ 3,465,160 |
Note 4 - Leases (Continuing Ope
Note 4 - Leases (Continuing Operations) | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Lessee, Operating and Finance Leases [Text Block] | Note 4 As a result of the adoption of ASC 842, $182,624, $190,173 April 1, 2019, Operating leases are included in other current assets and operating lease obligations, short and long term on the unaudited condensed consolidated balance sheets. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not There are no $3,243, $1,242 $2,001 September 30, 2020, no |
Note 5 - Notes Payable and Line
Note 5 - Notes Payable and Line of Credit | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 5 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. $521,067 20.3% $178,933 To date, the company has made principal payments totaling $330,555 $369,445 September 30, 2020 six September 30, 2020 $12,009 September 30, 2020 $ ( 1,919 On August 10, 2020, 11 $190,272 July 31, 2021, no no 15% 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 ( 11 $470,000 September 30, 2020 485,000 $15,000. $19,420 six September 30, 2020 485,000 September 30, 2020 8% May 7, 2020 On May 7, 2020, $135,000 15,000 $150,000 8.0% first $8,000,000 10 11 8,002,500 $0.04. $272,085 $49,525 $222,560. 150,000 six September 30, 2020 $154,964 $4,964 $150,000 September 30, 2020 $0. October 5, 2020. 8% July 24, 2020 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 11 3 July 24 may may September 30, 2020 $125,000. $1,162 six September 30, 2020 Summary of Notes and Convertible Notes Payable As of September 30, 2020 As of September 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (1,919 ) $ 367,526 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 125,000 - 125,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (7,705 ) 1,249,295 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 - 1,271,863 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,264,594 - 3,264,594 Total short-term notes payable 6,922,902 (9,624 ) 6,913,278 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 6,437,902 $ (9,624 ) $ 6,428,278 |
Note 6 - Convertible Notes
Note 6 - Convertible Notes | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Convertible Debt [Text Block] | Note 6 March 2017 $2M In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 July 2017 $7.2M In July, 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 $3,950,191 As of September 30, 2020 1,249,295 ( 7,705 March 2017 July 2017 $234,998. six September 30, 2020 $185,448, $147,635 As of September 30, 2020 $997,000 March July 2017 not 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020 8,823,529 $0.17 100% $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 $17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019 $41,863 $0.11 The Company evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, 110,000 $0.11 1,000,000 $9,579 $100,421. 1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796 March 31, 2020. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the six September 30, 2020 $460,495 $51,014 $409,481 September 30, 2020 1,271,863 no The Company defaulted on the amended CSW Note due to non-payment of quarterly interest payments and for nonpayment of an income tax liability related to the March 31, 2018 5 ten 11 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. $440,000 $265,000 $175,000 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 On April 22, 2020, 10%. $9,559 10% $276,500 10% On May 20, 2020, not July 14, 2020, $3,264,594 15% not 10 During the six September 30, 2020 $275,310, $29,831 $140,833 $104,646 no $3,264,594. |
Note 7 - Capital Transactions
Note 7 - Capital Transactions | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | Note 7 Sale of Common Stock and Exercise of Warrants On April 1, 2020, $0.03 $.05 4,991,084 six September 30, 2020 136,081 ( 15,121 During the quarter ended September 30, 2020 3,500,000 one $0.03 ten $105,000 At September 30, 2020 79,488,161 $0.25 $1.00 13,366,334 $0.28 |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | Note 8 On September 18, 2017 five two five The contract includes the Company's commitment to make an annual research investments of $500,000 50% 10 $250,000 $500,000 three $750,000. September one August 4, 2020, first $250,000 twelve September 30, 2020, twelve 50% 50% 25% On August 24, 2020, $250,000 no 10 Tara “Dee” Russell filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 15, 2019. July 26, 2019. not not On April 22, 2020, 6 May 20, 2020, July 14, 2020, $3,264,594 15% not 10 September 30, 2020 $3,369,240 $104,646 On April 22, 2020, $73,050 September 17, 2020, $25,000 $48,050. From time to time, the Company may not |
Note 9 - Related Party Transact
Note 9 - Related Party Transactions | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 9 As of September 30, 2020 710,075 $532,130 $112,087 $65,858 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $ 151,923 first 10 August 4, 2020, first |
Note 10 - Sale of Membership In
Note 10 - Sale of Membership Interests in GB Sciences Louisiana, LLC | 6 Months Ended |
Sep. 30, 2020 | |
GB Sciences Louisiana, LLC, Sale of Equity [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 10 On February 12, 2018, 15% $3 35% 5% $1 $7.0 49.99%. On November 15, 2019, 50.01% $8,000,000 may $8,000,000 On August 24, 2020, $5,224,423, $324,423 $4,900,000 October 15, 2020, $8,000,000 $250,000 8 no $750,000 September 1, 2020 $500,000. August 24, 2020 March 31, 2020 5,224,423 $1,895,434 March 31, 2020 The Company granted forbearance of the June 1, 2020 19 August 4, 2020, $250,000 twelve September 2020 ( 8 9 $189,423 On September 30, 2020, second $500,000 September 30, 2020 4,350,000 On October 15, 2020 $4,350,000 October 15, 2020, $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020. |
Note 11 - Sale of Membership In
Note 11 - Sale of Membership Interests in Nevada Subsidiaries | 6 Months Ended |
Sep. 30, 2020 | |
Nevada Subsidiaries [Member] | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 11 On November 15, 2019, 75% $3.0 $3.0 $470,000 5 8% 8% February 28, 2019 ( 6 On March 24, 2020, 100% $4,000,000 $4,000,000 8% 36 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019 ( 6 July 24 $4,000,000 3 July 24 125,000 July 24 5 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017, Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's condensed consolidated financial statements. |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 6 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 12 Capital Transactions Subsequent to September 30, 2020, 1,246,750 $0.03 $33,663, $3,740 Note Receivable On October 15, 2020 $4,350,000 October 15, 2020 August 24, 2020 10 $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020. Note Payable On October 5, 2020, $150,000 8% May 7, 2020 ( 5 On October 20, 2020, $75,000 8% July 24, 2020 ( 5 $200,000. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements of GB Sciences, Inc. (the “Company,” “We” or “Us”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 8 X. not not may March 31, 2021. March 31, 2020 not 10 March 31, 2020 |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassifications Certain reclassifications have been made to the comparative period amounts to conform to the current period presentation. Certain items on the unaudited balance sheets and statements of operations and cash flows have been reclassified to conform with current period presentation. The assets, liabilities, income, and cash flows of GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified to discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 10 11 |
Discontinued Operations, Policy [Policy Text Block] | Discontinued Operations Refer to Note 3. |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Long-Lived Assets Property and equipment comprise a significant portion of our total assets. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not No September 30, 2020 |
Inventory, Policy [Policy Text Block] | Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first |
Debt, Policy [Policy Text Block] | Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, 00 27, No. 98 5 first 718 The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only current revenue source is from sales of cannabis, a distinct physical good. Under ASC 606, may may one 606 not |
Earnings Per Share, Policy [Policy Text Block] | Earnings/(loss) per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 153,637,853 158,404,020 September 30, 2020 March 31, 2020 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements Recently Adopted Standards In June 2016, No. 2016 13, 326 2016 13" 326 326 326 2016 13 not not December 15, 2022, In August 2018, 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, April 1, 2020. not All other newly issued accounting pronouncements but not not |
Note 3 - Discontinued Operati_2
Note 3 - Discontinued Operations (Tables) | 6 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Disposal Groups, Including Discontinued Operations [Table Text Block] | September 30, 2020 March 31, 2020 Continuing Nevada Subsidiaries Total Continuing Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 545,020 $ 149,221 $ 694,241 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 346,058 346,058 - 117,967 117,967 Inventory, net - 1,439,320 1,439,320 - 1,445,839 1,445,839 Prepaid and other current assets 18,776 62,438 81,214 18,776 42,109 60,885 Note receivable 4,350,000 - 4,350,000 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 4,913,796 1,997,037 6,910,833 5,245,605 1,755,275 7,000,880 Property and equipment, net 31,278 5,113,829 5,145,107 37,821 5,496,012 5,533,833 Intangible assets, net 1,545,355 571,265 2,116,620 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 81,504 81,504 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 6,490,429 $ 7,763,635 $ 14,254,064 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 2,346,652 $ 607,766 $ 2,954,418 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 479,255 79,123 558,378 366,865 30,787 397,652 Accrued expenses 1,205,248 48,010 1,253,258 813,618 74,394 888,012 Notes payable, net 6,428,278 485,000 6,913,278 5,054,728 480,000 5,534,728 Indebtedness to related parties 710,075 - 710,075 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable 620,856 - 620,856 592,982 - 592,982 Finance lease obligations, current - 128,212 128,212 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 11,790,364 1,348,111 13,138,475 9,479,677 1,406,080 10,885,757 Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,465,160 3,465,160 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 11,790,364 $ 4,813,271 $ 16,603,635 $ 9,479,677 $ 4,961,685 $ 14,441,362 For the Three Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,264,271 $ 1,264,271 $ - $ 1,548,705 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) - (2,237,779 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 - (689,074 ) (689,074 ) General and administrative expenses 491,818 81,464 573,282 1,291,232 536,814 1,828,046 INCOME/(LOSS) FROM OPERATIONS (491,818 ) 323,739 (168,079 ) (1,291,232 ) (1,225,888 ) (2,517,120 ) OTHER INCOME/(EXPENSE) Interest expense (410,946 ) (128,201 ) (539,147 ) (352,736 ) (185,599 ) (538,335 ) Other income/(expense) (1,750 ) (77,448 ) (79,198 ) 92,707 (23,250 ) 69,457 Total other expense (412,696 ) (205,649 ) (618,345 ) (260,029 ) (208,849 ) (468,878 ) INCOME/(LOSS) BEFORE INCOME TAXES (904,514 ) 118,090 (786,424 ) (1,551,261 ) (1,434,737 ) (2,985,998 ) Income tax expense (19,034 ) - (19,034 ) 57,392 - 57,392 NET INCOME/(LOSS) $ (923,548 ) $ 118,090 $ (805,458 ) $ (1,493,869 ) $ (1,434,737 ) $ (2,928,606 ) For the Six Months Ended September 30, 2020 2019 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 1,815,468 $ 1,815,468 $ - $ 2,459,381 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) - (2,862,148 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 - (402,767 ) (402,767 ) General and administrative expenses 1,007,071 370,920 1,377,991 3,082,697 1,012,737 4,095,434 INCOME/(LOSS) FROM OPERATIONS (1,007,071 ) 93,685 (913,386 ) (3,082,697 ) (1,415,504 ) (4,498,201 ) OTHER INCOME/(EXPENSE) Interest expense (1,082,874 ) (261,143 ) (1,344,017 ) (664,937 ) (373,809 ) (1,038,746 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other income/(expense) (3,374 ) (77,448 ) (80,822 ) 92,707 (23,250 ) 69,457 Total other expense (1,372,307 ) (338,591 ) (1,710,898 ) (572,230 ) (397,059 ) (969,289 ) LOSS BEFORE INCOME TAXES (2,379,378 ) (244,906 ) (2,624,284 ) (3,654,927 ) (1,812,563 ) (5,467,490 ) Income tax expense (27,874 ) - (27,874 ) - - - NET LOSS $ (2,407,252 ) $ (244,906 ) $ (2,652,158 ) $ (3,654,927 ) $ (1,812,563 ) $ (5,467,490 ) For the Three Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,264,271 $ 1,264,271 $ 377,007 $ 1,171,698 $ 1,548,705 Cost of goods sold - (859,068 ) (859,068 ) (380,629 ) (1,857,150 ) (2,237,779 ) Gross profit/(loss) - 405,203 405,203 (3,622 ) (685,452 ) (689,074 ) General and administrative expenses - 81,464 81,464 424,732 112,082 536,814 INCOME/(LOSS) FROM OPERATIONS - 323,739 323,739 (428,354 ) (797,534 ) (1,225,888 ) OTHER EXPENSE Interest expense - (128,201 ) (128,201 ) (62,777 ) (122,822 ) (185,599 ) Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (205,649 ) (205,649 ) (62,777 ) (146,072 ) (208,849 ) INCOME/(LOSS) BEFORE INCOME TAXES - 118,090 118,090 (491,131 ) (943,606 ) (1,434,737 ) Income tax expense - - - - - - NET INCOME/(LOSS) $ - $ 118,090 $ 118,090 $ (491,131 ) $ (943,606 ) $ (1,434,737 ) For the Six Months Ended September 30, 2020 2019 GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations GB Sciences Louisiana, LLC Nevada Operations Total Discontinued Operations Sales revenue $ - $ 1,815,468 $ 1,815,468 $ 377,007 $ 2,082,374 $ 2,459,381 Cost of goods sold - (1,350,863 ) (1,350,863 ) (380,629 ) (2,481,519 ) (2,862,148 ) Gross profit/(loss) - 464,605 464,605 (3,622 ) (399,145 ) (402,767 ) General and administrative expenses - 370,920 370,920 626,571 386,166 1,012,737 INCOME/(LOSS) FROM OPERATIONS - 93,685 93,685 (630,193 ) (785,311 ) (1,415,504 ) OTHER EXPENSE Interest expense - (261,143 ) (261,143 ) (125,372 ) (248,437 ) (373,809 ) Debt default penalty - - - - - - Other expense - (77,448 ) (77,448 ) - (23,250 ) (23,250 ) Total other expense - (338,591 ) (338,591 ) (125,372 ) (271,687 ) (397,059 ) LOSS BEFORE INCOME TAXES - (244,906 ) (244,906 ) (755,565 ) (1,056,998 ) (1,812,563 ) Income tax expense - - - - - - NET LOSS $ - $ (244,906 ) $ (244,906 ) $ (755,565 ) $ (1,056,998 ) $ (1,812,563 ) |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | September 30, 2020 March 31, 2020 Raw materials $ 2,677 $ 91,465 Work in progress 789,482 1,166,511 Finished goods 653,314 466,319 Subtotal 1,445,473 1,724,295 Allowance to reduce inventory to net realizable value (6,153 ) (278,456 ) Total inventory, net $ 1,439,320 $ 1,445,839 |
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block] | Year Ending March 31, Finance Leases 2021 (6 months) $ 266,188 2022 544,296 2023 560,625 2024 577,444 2025 594,767 Thereafter 3,781,102 Total minimum lease payments 6,324,422 Less: Amount representing interest (2,731,050 ) Present value of minimum lease payments 3,593,372 Less: Current maturities of capital lease obligations (128,212 ) Long-term capital lease obligations $ 3,465,160 |
Note 5 - Notes Payable and Li_2
Note 5 - Notes Payable and Line of Credit (Tables) | 6 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | As of September 30, 2020 Short-Term Notes Payable Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (1,919 ) $ 367,526 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 125,000 - 125,000 8% Note Payable dated May 7, 2020 (Note 5) 150,000 - 150,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (7,705 ) 1,249,295 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 - 1,271,863 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 3,264,594 - 3,264,594 Total short-term notes payable 6,922,902 (9,624 ) 6,913,278 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short-term notes payable classified as continuing operations $ 6,437,902 $ (9,624 ) $ 6,428,278 |
Note 1 - Background and Signi_2
Note 1 - Background and Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 6 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Mar. 31, 2020 | |
Impairment of Long-Lived Assets Held-for-use | $ 0 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 153,637,853 | 158,404,020 |
Note 2 - Going Concern (Details
Note 2 - Going Concern (Details Textual) - USD ($) | 6 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Mar. 31, 2020 | |
Retained Earnings (Accumulated Deficit), Ending Balance | $ (100,056,626) | $ (97,387,205) | |
Working Capital (Deficit) | (6,227,642) | (3,884,877) | |
Net Cash Provided by (Used in) Operating Activities, Total | (212,854) | $ (3,546,457) | |
Cash Provided by (Used in) Operating Activities, Discontinued Operations | (10,602) | $ (1,758,120) | |
Discontinued Operations [Member] | |||
Working Capital (Deficit) | $ 648,926 | $ 349,195 |
Note 3 - Discontinued Operati_3
Note 3 - Discontinued Operations (Details Textual) - USD ($) | 6 Months Ended | ||
Sep. 30, 2020 | Mar. 31, 2020 | Apr. 01, 2019 | |
Lessee, Operating Lease, Discount Rate | 17.00% | ||
Operating Lease, Cost | $ 3,243 | ||
Operating Lease, Interest Expense | 1,242 | ||
Operating Lease, Right-of-Use Asset, Amortization Expense | 2,001 | ||
Discontinued Operations [Member] | |||
Operating Lease, Right-of-Use Asset | $ 26,685 | ||
Finance Lease Costs | 286,436 | ||
Finance Lease, Interest Expense | 209,086 | ||
Finance Lease, Right-of-Use Asset, Amortization | 77,350 | ||
Continuing Operations [Member] | |||
Operating Lease, Right-of-Use Asset | |||
Operating Lease, Cost | 3,243 | ||
Operating Lease, Interest Expense | 1,242 | ||
Operating Lease, Right-of-Use Asset, Amortization Expense | $ 2,001 | ||
Minimum [Member] | |||
Lessee, Finance Lease, Discount Rate | 10.20% | ||
Maximum [Member] | |||
Lessee, Finance Lease, Discount Rate | 11.50% | ||
Accounting Standards Update 2016-02 [Member] | |||
Operating Lease, Right-of-Use Asset | $ 182,624 | ||
Operating Lease, Liability, Total | $ 190,173 | ||
GB Sciences Louisiana, LLC [Member] | |||
Disposal Group, Including Discontinued Operation, Assets, Total | $ 0 | 0 | |
Disposal Group, Including Discontinued Operation, Liabilities, Total | $ 0 | $ 0 |
Note 3 - Discontinued Operati_4
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Mar. 31, 2020 | |
Cash and cash equivalents | $ 545,020 | $ 545,020 | $ 2,406 | ||
Prepaid and other current assets | 18,776 | 18,776 | 18,776 | ||
Note receivable | 4,350,000 | 4,350,000 | 5,224,423 | ||
TOTAL CURRENT ASSETS | 6,910,833 | 6,910,833 | 7,000,880 | ||
Property and equipment, net | 31,278 | 31,278 | 37,821 | ||
Intangible assets, net | 1,545,355 | 1,545,355 | 1,128,702 | ||
TOTAL ASSETS | 14,254,064 | 14,254,064 | 14,352,868 | ||
Accounts payable | 2,346,652 | 2,346,652 | 1,913,049 | ||
Accrued interest | 479,255 | 479,255 | 366,865 | ||
Accrued liabilities | 1,205,248 | 1,205,248 | 813,618 | ||
Notes payable, net | 6,428,278 | 6,428,278 | 5,054,728 | ||
Indebtedness to related parties | 710,075 | 710,075 | 586,512 | ||
Note payable to related party | 151,923 | ||||
Income tax payable | 620,856 | 620,856 | 592,982 | ||
TOTAL CURRENT LIABILITIES | 13,138,475 | 13,138,475 | 10,885,757 | ||
TOTAL LIABILITIES | 16,603,635 | 16,603,635 | 14,441,362 | ||
Sales revenue | |||||
Cost of goods sold | |||||
Gross profit/(loss) | |||||
General and administrative expenses | 491,818 | 1,291,232 | 1,007,071 | 3,082,697 | |
INCOME/(LOSS) FROM OPERATIONS | (491,818) | (1,291,232) | (1,007,071) | (3,082,697) | |
Interest expense | (410,946) | (352,736) | (1,082,874) | (664,937) | |
Other income/(expense) | (1,750) | 92,707 | (3,374) | 92,707 | |
Total other expense | (412,696) | (260,029) | (1,372,307) | (572,230) | |
INCOME/(LOSS) BEFORE INCOME TAXES | (904,514) | (1,551,261) | (2,379,378) | (3,654,927) | |
Income tax benefit/(expense) | (19,034) | 57,392 | (27,874) | ||
Net loss | (805,458) | (2,928,606) | (2,652,158) | (5,467,490) | |
Debt default penalty | (286,059) | ||||
NET INCOME/(LOSS) | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||||
Inventory, net | 1,439,320 | 1,439,320 | 1,445,839 | ||
Finance lease obligations, current | 128,212 | 128,212 | |||
Long-term capital lease obligations, finance leases | 3,465,160 | 3,465,160 | |||
Sales revenue | 1,264,271 | 1,548,705 | 1,815,468 | 2,459,381 | |
Cost of goods sold | (859,068) | (2,237,779) | (1,350,863) | (2,862,148) | |
Gross profit/(loss) | 405,203 | (689,074) | 464,605 | (402,767) | |
General and administrative expenses | 81,464 | 536,814 | 370,920 | 1,012,737 | |
INCOME/(LOSS) FROM OPERATIONS | 323,739 | (1,225,888) | 93,685 | (1,415,504) | |
Interest expense | (128,201) | (185,599) | (261,143) | (373,809) | |
Other expense | (77,448) | (23,250) | (77,448) | (23,250) | |
Total other expense | (205,649) | (208,849) | (338,591) | (397,059) | |
INCOME/(LOSS) BEFORE INCOME TAXES | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Income tax expense | |||||
NET INCOME/(LOSS) | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Debt default penalty | |||||
GB Sciences Louisiana, LLC [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||||
Sales revenue | 377,007 | 377,007 | |||
Cost of goods sold | (380,629) | (380,629) | |||
Gross profit/(loss) | (3,622) | (3,622) | |||
General and administrative expenses | 424,732 | 626,571 | |||
INCOME/(LOSS) FROM OPERATIONS | (428,354) | (630,193) | |||
Interest expense | (62,777) | (125,372) | |||
Other expense | |||||
Total other expense | (62,777) | (125,372) | |||
INCOME/(LOSS) BEFORE INCOME TAXES | (491,131) | (755,565) | |||
Income tax expense | |||||
NET INCOME/(LOSS) | (491,131) | (755,565) | |||
Debt default penalty | |||||
Nevada Subsidiaries [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | |||||
Sales revenue | 1,264,271 | 1,171,698 | 1,815,468 | 2,082,374 | |
Cost of goods sold | (859,068) | (1,857,150) | (1,350,863) | (2,481,519) | |
Gross profit/(loss) | 405,203 | (685,452) | 464,605 | (399,145) | |
General and administrative expenses | 81,464 | 112,082 | 370,920 | 386,166 | |
INCOME/(LOSS) FROM OPERATIONS | 323,739 | (797,534) | 93,685 | (785,311) | |
Interest expense | (128,201) | (122,822) | (261,143) | (248,437) | |
Other expense | (77,448) | (23,250) | (77,448) | (23,250) | |
Total other expense | (205,649) | (146,072) | (338,591) | (271,687) | |
INCOME/(LOSS) BEFORE INCOME TAXES | 118,090 | (943,606) | (244,906) | (1,056,998) | |
Income tax expense | |||||
NET INCOME/(LOSS) | 118,090 | (943,606) | (244,906) | (1,056,998) | |
Debt default penalty | |||||
Continuing Operations [Member] | |||||
Cash and cash equivalents | 545,020 | 545,020 | 2,406 | ||
Accounts receivable, net | |||||
Inventory, net | |||||
Prepaid and other current assets | 18,776 | 18,776 | 18,776 | ||
Note receivable | 4,350,000 | 4,350,000 | 5,224,423 | ||
TOTAL CURRENT ASSETS | 4,913,796 | 4,913,796 | 5,245,605 | ||
Property and equipment, net | 31,278 | 31,278 | 37,821 | ||
Intangible assets, net | 1,545,355 | 1,545,355 | 1,128,702 | ||
Deposits and other noncurrent assets | |||||
Operating lease right-of-use assets, net | |||||
TOTAL ASSETS | 6,490,429 | 6,490,429 | 6,412,128 | ||
Accounts payable | 2,346,652 | 2,346,652 | 1,913,049 | ||
Accrued interest | 479,255 | 479,255 | 366,865 | ||
Accrued liabilities | 1,205,248 | 1,205,248 | 813,618 | ||
Notes payable, net | 6,428,278 | 6,428,278 | 5,054,728 | ||
Indebtedness to related parties | 710,075 | 710,075 | 586,512 | ||
Note payable to related party | 151,923 | ||||
Income tax payable | 620,856 | 620,856 | 592,982 | ||
Finance lease obligations, current | |||||
Operating lease obligations, current | |||||
TOTAL CURRENT LIABILITIES | 11,790,364 | 11,790,364 | 9,479,677 | ||
Operating lease obligations, long term | |||||
Long-term capital lease obligations, finance leases | |||||
TOTAL LIABILITIES | 11,790,364 | 11,790,364 | 9,479,677 | ||
Sales revenue | |||||
Cost of goods sold | |||||
Gross profit/(loss) | |||||
General and administrative expenses | 491,818 | 1,291,232 | 1,007,071 | 3,082,697 | |
INCOME/(LOSS) FROM OPERATIONS | (491,818) | (1,291,232) | (1,007,071) | (3,082,697) | |
Interest expense | (410,946) | (352,736) | (1,082,874) | (664,937) | |
Other income/(expense) | (1,750) | 92,707 | (3,374) | 92,707 | |
Total other expense | (412,696) | (260,029) | (1,372,307) | (572,230) | |
INCOME/(LOSS) BEFORE INCOME TAXES | (904,514) | (1,551,261) | (2,379,378) | (3,654,927) | |
Income tax benefit/(expense) | (19,034) | 57,392 | (27,874) | ||
Net loss | (923,548) | (1,493,869) | (2,407,252) | (3,654,927) | |
Debt default penalty | (286,059) | ||||
Discontinued Operations [Member] | |||||
Cash and cash equivalents | 149,221 | 149,221 | 149,360 | ||
Accounts receivable, net | 346,058 | 346,058 | 117,967 | ||
Inventory, net | 1,439,320 | 1,439,320 | 1,445,839 | ||
Prepaid and other current assets | 62,438 | 62,438 | 42,109 | ||
Note receivable | |||||
TOTAL CURRENT ASSETS | 1,997,037 | 1,997,037 | 1,755,275 | ||
Property and equipment, net | 5,113,829 | 5,113,829 | 5,496,012 | ||
Intangible assets, net | 571,265 | 571,265 | 571,264 | ||
Deposits and other noncurrent assets | 81,504 | 81,504 | 91,504 | ||
Operating lease right-of-use assets, net | 26,685 | ||||
TOTAL ASSETS | 7,763,635 | 7,763,635 | 7,940,740 | ||
Accounts payable | 607,766 | 607,766 | 646,865 | ||
Accrued interest | 79,123 | 79,123 | 30,787 | ||
Accrued liabilities | 48,010 | 48,010 | 74,394 | ||
Notes payable, net | 485,000 | 485,000 | 480,000 | ||
Indebtedness to related parties | |||||
Note payable to related party | |||||
Income tax payable | |||||
Finance lease obligations, current | 128,212 | 128,212 | 166,769 | ||
Operating lease obligations, current | 7,265 | ||||
TOTAL CURRENT LIABILITIES | 1,348,111 | 1,348,111 | 1,406,080 | ||
Operating lease obligations, long term | 22,515 | ||||
Long-term capital lease obligations, finance leases | 3,465,160 | 3,465,160 | 3,533,090 | ||
TOTAL LIABILITIES | 4,813,271 | 4,813,271 | 4,961,685 | ||
Sales revenue | 1,264,271 | 1,548,705 | 1,815,468 | 2,459,381 | |
Cost of goods sold | (859,068) | (2,237,779) | (1,350,863) | (2,862,148) | |
Gross profit/(loss) | 405,203 | (689,074) | 464,605 | (402,767) | |
General and administrative expenses | 81,464 | 536,814 | 370,920 | 1,012,737 | |
INCOME/(LOSS) FROM OPERATIONS | 323,739 | (1,225,888) | 93,685 | (1,415,504) | |
Interest expense | (128,201) | (185,599) | (261,143) | (373,809) | |
Other income/(expense) | (77,448) | (23,250) | (77,448) | (23,250) | |
Total other expense | (205,649) | (208,849) | (338,591) | (397,059) | |
INCOME/(LOSS) BEFORE INCOME TAXES | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Income tax benefit/(expense) | |||||
Net loss | 118,090 | (1,434,737) | (244,906) | (1,812,563) | |
Debt default penalty | |||||
Segment, Continuing and Discontinued Operations [Member] | |||||
Cash and cash equivalents | 694,241 | 694,241 | 151,766 | ||
Accounts receivable, net | 346,058 | 346,058 | 117,967 | ||
Inventory, net | 1,439,320 | 1,439,320 | 1,445,839 | ||
Prepaid and other current assets | 81,214 | 81,214 | 60,885 | ||
Note receivable | 4,350,000 | 4,350,000 | 5,224,423 | ||
TOTAL CURRENT ASSETS | 6,910,833 | 6,910,833 | 7,000,880 | ||
Property and equipment, net | 5,145,107 | 5,145,107 | 5,533,833 | ||
Intangible assets, net | 2,116,620 | 2,116,620 | 1,699,966 | ||
Deposits and other noncurrent assets | 81,504 | 81,504 | 91,504 | ||
Operating lease right-of-use assets, net | 26,685 | ||||
TOTAL ASSETS | 14,254,064 | 14,254,064 | 14,352,868 | ||
Accounts payable | 2,954,418 | 2,954,418 | 2,559,914 | ||
Accrued interest | 558,378 | 558,378 | 397,652 | ||
Accrued liabilities | 1,253,258 | 1,253,258 | 888,012 | ||
Notes payable, net | 6,913,278 | 6,913,278 | 5,534,728 | ||
Indebtedness to related parties | 710,075 | 710,075 | 586,512 | ||
Note payable to related party | 151,923 | ||||
Income tax payable | 620,856 | 620,856 | 592,982 | ||
Finance lease obligations, current | 128,212 | 128,212 | 166,769 | ||
Operating lease obligations, current | 7,265 | ||||
TOTAL CURRENT LIABILITIES | 13,138,475 | 13,138,475 | 10,885,757 | ||
Operating lease obligations, long term | 22,515 | ||||
Long-term capital lease obligations, finance leases | 3,465,160 | 3,465,160 | 3,533,090 | ||
TOTAL LIABILITIES | 16,603,635 | 16,603,635 | $ 14,441,362 | ||
Sales revenue | 1,264,271 | 1,548,705 | 1,815,468 | 2,459,381 | |
Cost of goods sold | (859,068) | (2,237,779) | (1,350,863) | (2,862,148) | |
Gross profit/(loss) | 405,203 | (689,074) | 464,605 | (402,767) | |
General and administrative expenses | 573,282 | 1,828,046 | 1,377,991 | 4,095,434 | |
INCOME/(LOSS) FROM OPERATIONS | (168,079) | (2,517,120) | (913,386) | (4,498,201) | |
Interest expense | (539,147) | (538,335) | (1,344,017) | (1,038,746) | |
Other income/(expense) | (79,198) | 69,457 | (80,822) | 69,457 | |
Total other expense | (618,345) | (468,878) | (1,710,898) | (969,289) | |
INCOME/(LOSS) BEFORE INCOME TAXES | (786,424) | (2,985,998) | (2,624,284) | (5,467,490) | |
Income tax benefit/(expense) | (19,034) | 57,392 | (27,874) | ||
Net loss | $ (805,458) | $ (2,928,606) | (2,652,158) | (5,467,490) | |
Debt default penalty | $ (286,059) |
Note 3 - Discontinued Operati_5
Note 3 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($) | Sep. 30, 2020 | Mar. 31, 2020 |
Raw materials | $ 2,677 | $ 91,465 |
Work in progress | 789,482 | 1,166,511 |
Finished goods | 653,314 | 466,319 |
Subtotal | 1,445,473 | 1,724,295 |
Allowance to reduce inventory to net realizable value | (6,153) | (278,456) |
Total inventory, net | $ 1,439,320 | $ 1,445,839 |
Note 3 - Discontinued Operati_6
Note 3 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | Sep. 30, 2020USD ($) |
2021 (6 months), finance leases | $ 266,188 |
2022, finance leases | 544,296 |
2023, finance leases | 560,625 |
2024, finance leases | 577,444 |
2025, finance leases | 594,767 |
Thereafter, finance leases | 3,781,102 |
Total minimum lease payments, finance leases | 6,324,422 |
Less: Amount representing interest, finance leases | (2,731,050) |
Present value of minimum lease payments, finance leases | 3,593,372 |
Less: Current maturities of capital lease obligations, finance leases | (128,212) |
Long-term capital lease obligations, finance leases | $ 3,465,160 |
Note 4 - Leases (Continuing O_2
Note 4 - Leases (Continuing Operations) (Details Textual) - USD ($) | 6 Months Ended | |
Sep. 30, 2020 | Apr. 01, 2019 | |
Operating Lease, Cost | $ 3,243 | |
Operating Lease, Interest Expense | 1,242 | |
Operating Lease, Right-of-Use Asset, Amortization Expense | $ 2,001 | |
Accounting Standards Update 2016-02 [Member] | ||
Operating Lease, Right-of-Use Asset | $ 182,624 | |
Operating Lease, Liability, Total | $ 190,173 |
Note 5 - Notes Payable and Li_3
Note 5 - Notes Payable and Line of Credit (Details Textual) | May 07, 2020USD ($)$ / sharesshares | Oct. 23, 2017USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) | Aug. 10, 2020USD ($) | Jul. 24, 2020USD ($) | Jun. 30, 2020USD ($) | May 06, 2020USD ($) | Mar. 24, 2020USD ($) | Nov. 27, 2019USD ($) | Oct. 23, 2019USD ($) |
Proceeds from Lines of Credit, Total | $ 125,000 | ||||||||||||||
Payments of Debt Issuance Costs | 175,000 | ||||||||||||||
Interest Expense, Debt, Excluding Amortization | 26,804 | ||||||||||||||
Amortization of Debt Discount (Premium) | 748,956 | $ 434,750 | |||||||||||||
Repriced Preexisting Warrants with Convertible Debt Issuance [Member] | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 8,002,500 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.04 | ||||||||||||||
Warrants and Rights Outstanding | $ 272,085 | $ 49,525 | |||||||||||||
Fair Value Adjustment of Warrants | $ 222,560 | ||||||||||||||
Line of Credit [Member] | |||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | ||||||||||||||
Proceeds from Lines of Credit, Total | $ 485,000 | ||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Increased | 15,000 | ||||||||||||||
Interest Payable | $ 19,420 | $ 19,420 | 19,420 | 19,420 | $ 19,420 | ||||||||||
Long-term Line of Credit, Total | 485,000 | 485,000 | 485,000 | 485,000 | 485,000 | ||||||||||
Teco [Member] | |||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | ||||||||||||||
The July 24 Note [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||
The July 24 Note [Member] | Revolving Credit Facility [Member] | |||||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 500,000 | ||||||||||||||
Proceeds from Lines of Credit, Total | 125,000 | ||||||||||||||
Interest and Debt Expense, Total | 1,162 | ||||||||||||||
The July 24 Note [Member] | Teco [Member] | |||||||||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | ||||||||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | ||||||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | |||||||||||||
Debt Instrument, Face Amount | $ 700,000 | ||||||||||||||
Debt Instrument, Term (Year) | 3 years | ||||||||||||||
Debt Instrument, Present Value | 521,067 | 521,067 | $ 521,067 | 521,067 | 521,067 | ||||||||||
Receivable with Imputed Interest, Effective Yield (Interest Rate) | 20.30% | ||||||||||||||
Debt Instrument, Unamortized Discount, Total | 1,919 | 1,919 | $ 1,919 | 1,919 | 1,919 | $ 178,933 | |||||||||
Repayments of Debt | 330,555 | ||||||||||||||
Long-term Debt, Gross | $ 369,445 | 369,445 | 369,445 | $ 369,445 | $ 369,445 | ||||||||||
Interest Expense, Debt, Total | 12,009 | ||||||||||||||
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member] | |||||||||||||||
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition | $ 190,272 | ||||||||||||||
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition | 15.00% | ||||||||||||||
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member] | |||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||
Debt Instrument, Face Amount | $ 150,000 | ||||||||||||||
Debt Instrument, Unamortized Discount, Total | 150,000 | $ 0 | |||||||||||||
Proceeds from Issuance of Long-term Debt, Net | 135,000 | ||||||||||||||
Payments of Debt Issuance Costs | $ 15,000 | ||||||||||||||
Repayments of Long-term Debt, Total | $ 8,000,000 | ||||||||||||||
Interest and Debt Expense, Total | 154,964 | ||||||||||||||
Interest Expense, Debt, Excluding Amortization | 4,964 | ||||||||||||||
Amortization of Debt Discount (Premium) | $ 150,000 | ||||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | |||||||||||||||
Payments to Acquire License | $ 500,000 | ||||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member] | |||||||||||||||
Ownership of Licence | 100.00% | ||||||||||||||
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member] | |||||||||||||||
Ownership of Licence | 100.00% |
Note 5 - Notes Payable and Li_4
Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($) | Sep. 30, 2020 | Mar. 31, 2020 | Apr. 23, 2019 |
Discount, short-term notes payable | $ (9,624) | $ (608,580) | |
Discount, short-term notes payable | (9,624) | $ (608,580) | |
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | |||
Face Value, short-term notes payable | 369,445 | ||
Discount, short-term notes payable | (1,919) | ||
Carrying Value, short-term notes payable | 367,526 | ||
Face Value, short-term notes payable | 369,445 | ||
Discount, short-term notes payable | (1,919) | ||
Carrying Value, short-term notes payable | 367,526 | ||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Issued to Investor on May 7, 2020 [Member] | |||
Face Value, short-term notes payable | 150,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 150,000 | ||
Face Value, short-term notes payable | 150,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 150,000 | ||
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member] | |||
Face Value, short-term notes payable | 1,257,000 | ||
Discount, short-term notes payable | (7,705) | ||
Carrying Value, short-term notes payable | 1,249,295 | ||
Face Value, short-term notes payable | 1,257,000 | ||
Discount, short-term notes payable | (7,705) | ||
Carrying Value, short-term notes payable | 1,249,295 | ||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||
Face Value, short-term notes payable | 3,264,594 | $ 2,765,000 | |
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 3,264,594 | ||
Face Value, short-term notes payable | 3,264,594 | $ 2,765,000 | |
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 3,264,594 | ||
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member] | |||
Face Value, short-term notes payable | 485,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 485,000 | ||
Face Value, short-term notes payable | 485,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 485,000 | ||
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member] | |||
Face Value, short-term notes payable | 125,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 125,000 | ||
Face Value, short-term notes payable | 125,000 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 125,000 | ||
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||
Face Value, short-term notes payable | 1,271,863 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 1,271,863 | ||
Face Value, short-term notes payable | 1,271,863 | ||
Discount, short-term notes payable | |||
Carrying Value, short-term notes payable | 1,271,863 | ||
Promissory Note [Member] | |||
Face Value, short-term notes payable | 6,922,902 | ||
Discount, short-term notes payable | (9,624) | ||
Carrying Value, short-term notes payable | 6,913,278 | ||
Face Value, short-term notes payable | 6,922,902 | ||
Discount, short-term notes payable | (9,624) | ||
Carrying Value, short-term notes payable | 6,913,278 | ||
Less: Notes payable classified as discontinued operations, face value | (485,000) | ||
Less: Notes payable classified as discontinued operations, discount | |||
Less: Notes payable classified as discontinued operations, carrying value | (485,000) | ||
Total short-term notes payable classified as continuing operations, face value | 6,437,902 | ||
Total short-term notes payable classified as continuing operations, discount | (9,624) | ||
Total short-term notes payable classified as continuing operations, carrying value | $ 6,428,278 |
Note 6 - Convertible Notes (Det
Note 6 - Convertible Notes (Details Textual) | Jul. 14, 2020USD ($) | Apr. 22, 2020USD ($) | Dec. 16, 2019USD ($)$ / sharesshares | Nov. 27, 2019USD ($)$ / shares | Nov. 18, 2019USD ($)$ / sharesshares | Oct. 30, 2019USD ($)$ / sharesshares | Oct. 23, 2019USD ($)$ / shares | Aug. 01, 2019USD ($)$ / sharesshares | Jul. 12, 2019USD ($)$ / shares | May 28, 2019USD ($)$ / sharesshares | Apr. 23, 2019USD ($)$ / shares | Feb. 28, 2019USD ($)$ / shares | Jul. 31, 2017USD ($)$ / shares | Mar. 31, 2017USD ($)$ / shares | May 31, 2017USD ($)$ / sharesshares | Sep. 30, 2020USD ($)$ / shares | Sep. 30, 2019USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Mar. 31, 2020USD ($) |
Interest Payable, Current | $ 479,255 | $ 366,865 | |||||||||||||||||
Amortization of Debt Discount (Premium) | 748,956 | $ 434,750 | |||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | (124,158) | ||||||||||||||||||
Interest Expense, Debt, Excluding Amortization | 26,804 | ||||||||||||||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | |||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 15.00% | ||||||||||||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | ||||||||||||||||||
Minimum [Member] | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||
Maximum [Member] | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1 | ||||||||||||||||||
Warrants Issued in March 2017 Convertible Note Offering [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.60 | $ 0.60 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | 3 years | |||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 8,000,000 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||
Warrants Related to July 2017 Convertible Note Offering [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Number of Warrants | 4,000 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.65 | $ 0.60 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||||||||
Class of Warrant or Right, Issued (in shares) | shares | 28,804,000 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares | 1 | ||||||||||||||||||
Convertible Notes Payable [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 150,000 | $ 133,806 | |||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | |||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | ||||||||||||||||||
Debt Instrument, Face Amount | $ 2,000,000 | ||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 1,933,693 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 904,690 | ||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 1,029,003 | ||||||||||||||||||
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 8,000,000 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||
Debt Instrument, Face Amount Per Note | $ 1,000 | ||||||||||||||||||
Debt Instrument, Face Amount | $ 7,201,000 | ||||||||||||||||||
Debt Instrument, Term (Year) | 3 years | 3 years | |||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 7,705 | $ 7,092,796 | |||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 3,142,605 | ||||||||||||||||||
Debt Instrument, Convertible, Discount, Fair Value of Warrants | $ 3,950,191 | ||||||||||||||||||
Long-term Debt, Gross | 1,249,295 | ||||||||||||||||||
Interest Payable, Current | 234,998 | ||||||||||||||||||
Interest Expense, Debt, Total | 185,448 | ||||||||||||||||||
Amortization of Debt Discount (Premium) | 147,635 | ||||||||||||||||||
Debt Default, Short-term Debt, Amount | 997,000 | ||||||||||||||||||
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 4,000 | 28,804,000 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.25 | ||||||||||||||||||
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.0375 | $ 0.06 | $ 0.17 | ||||||||||||||||
Debt Instrument, Face Amount | $ 2,765,000 | 3,264,594 | |||||||||||||||||
Debt Instrument, Unamortized Discount, Total | 265,000 | ||||||||||||||||||
Interest Expense, Debt, Total | 275,310 | ||||||||||||||||||
Amortization of Debt Discount (Premium) | 29,831 | ||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 50,000 | $ 75,000 | 125,000 | ||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 1,333,333 | 1,250,000 | |||||||||||||||||
Short-term Debt, Total | 3,264,594 | ||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total | 440,000 | ||||||||||||||||||
Payments for Brokerage Fees | $ 175,000 | ||||||||||||||||||
Induced Conversion of Convertible Debt Expense | $ 64,706 | ||||||||||||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 10.00% | ||||||||||||||||||
Debt Instrument, Debt Default, Interest Expense | $ 9,559 | ||||||||||||||||||
Debt Instrument, Debt Default, Principal Expense | $ 276,500 | ||||||||||||||||||
Debt Instrument, Debt Default, Increase in Principal Amount, Percent | 10.00% | ||||||||||||||||||
Interest Expense, Debt, Pre-judgment Interest | 140,833 | ||||||||||||||||||
Interest Expense, Debt, Post-judgment Interest | 104,646 | ||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net, Total | 0 | ||||||||||||||||||
Promissory Note [Member] | |||||||||||||||||||
Debt Instrument, Face Amount | 6,922,902 | ||||||||||||||||||
Short-term Debt, Total | 6,913,278 | ||||||||||||||||||
Promissory Note [Member] | July 2017 Convertible Note Offering [Member] | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.00% | ||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | |||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | 8.00% | 8.00% | |||||||||||||||
Debt Instrument, Face Amount | $ 1,500,000 | ||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ 584,842 | $ 9,579 | $ 17,225 | 0 | |||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 92,796 | $ 133,806 | $ 176,471 | ||||||||||||||||
Long-term Debt, Gross | 687,021 | 1,271,863 | |||||||||||||||||
Interest Expense, Debt, Total | 460,495 | ||||||||||||||||||
Amortization of Debt Discount (Premium) | 57,551 | 409,481 | |||||||||||||||||
Debt Conversion, Original Debt, Amount | 120,000 | 110,000 | 170,000 | ||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | (62,449) | $ 30,000 | (100,421) | 100,000 | (152,775) | ||||||||||||||
Short-term Debt, Total | $ 1,271,863 | 1,361,863 | $ 1,269,067 | $ 1,361,863 | 1,338,057 | $ 1,330,000 | |||||||||||||
Proceeds from Related Party Debt | 100,000 | ||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 41,863 | ||||||||||||||||||
Gain (Loss) on Extinguishment of Debt, Total | $ 0 | $ (124,158) | $ (92,796) | ||||||||||||||||
Interest Expense, Debt, Excluding Amortization | $ 51,014 | ||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Minimum [Member] | |||||||||||||||||||
Days to Cure Breach of Default After Notification From Lender | 5 | ||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Maximum [Member] | |||||||||||||||||||
Days to Cure Breach of Default After Notification From Lender | 10 | ||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member] | |||||||||||||||||||
Noncontrolling Interest, Ownership Percentage by Parent | 100.00% | ||||||||||||||||||
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | |||||||||||||||||||
Debt Instrument, Convertible, Number of Equity Instruments | 8,823,529 | ||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares | $ 0.04 | $ 0.04 | $ 0.08 | $ 0.11 | $ 0.11 | $ 0.17 | $ 0.17 | ||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 3,000,000 | 1,000,000 | 1,000,000 |
Note 7 - Capital Transactions (
Note 7 - Capital Transactions (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Apr. 01, 2020 | |
Proceeds from Warrant Exercises | $ 151,202 | $ 944,975 | ||
Class of Warrant or Right, Outstanding (in shares) | 79,488,161 | 79,488,161 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 13,366,334 | 13,366,334 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 0.28 | $ 0.28 | ||
Scientist and Researcher [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 3,500,000 | |||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) | $ 0.03 | |||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $ 105,000 | |||
Scientist and Researcher [Member] | Share-based Payment Arrangement, Option [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | |||
Minimum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.25 | 0.25 | ||
Maximum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1 | $ 1 | ||
Warrants Issued to Investors in Private Placements [Member] | ||||
Class of Warrant or Right, Exercises in Period (in shares) | 4,991,084 | |||
Proceeds from Warrant Exercises | $ 136,081 | |||
Brokerage Fees for Issuance of Common Stock and Warrants | $ 15,121 | |||
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.03 | |||
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member] | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.05 |
Note 8 - Commitments and Cont_2
Note 8 - Commitments and Contingencies (Details Textual) | Sep. 17, 2020USD ($) | Aug. 24, 2020USD ($) | Aug. 04, 2020USD ($) | Jul. 14, 2020USD ($) | Apr. 22, 2020USD ($) | Sep. 18, 2017USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) |
The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 10.00% | |||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | ||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 3,264,594 | |||||||
Debt Instrument, Debt Default, Interest Rate Penalty | 15.00% | |||||||
Repayment of Iliad Note [Member] | Judicial Ruling [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Convertible Notes Payable [Member] | ||||||||
Debt Instrument, Balance Due, Including Accrued Post-judgment Interest | $ 3,369,240 | $ 3,369,240 | ||||||
Debt Instrument, Accrued Post-judgment Interest | $ 104,646 | 104,646 | ||||||
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member] | ||||||||
Loss Contingency, Damages Sought, Value | $ 73,050 | |||||||
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member] | ||||||||
Payments for Legal Settlements | $ 25,000 | |||||||
Reduction in Cost Basis of Fixed Asset Related to Litigation | $ 48,050 | |||||||
Agreement With Louisiana State University AgCenter [Member] | ||||||||
Term of Agreement (Year) | 5 years | 3 years | ||||||
Option to Renew Agreement, Amount | 2 | |||||||
Term of Agreement, Renewal (Year) | 5 years | |||||||
Research and Development Expense, Total | $ 500,000 | $ 250,000 | $ 750,000 | |||||
Annual Research Contributions | $ 250,000 | $ 250,000 |
Note 9 - Related Party Transa_2
Note 9 - Related Party Transactions (Details Textual) - USD ($) | Sep. 30, 2020 | Aug. 04, 2020 | Mar. 31, 2020 |
Notes Payable, Related Parties, Current | $ 151,923 | ||
John Davis [Member] | |||
Due to Related Parties, Total | $ 189,423 | ||
Notes Payable, Related Parties, Current | 151,923 | ||
Officers and Directors [Member] | |||
Due to Related Parties, Total | 710,075 | ||
Reimbursement for Business Expense, Related Parties | 65,858 | ||
Officer [Member] | |||
Unpaid Wages, Related Parties | 532,130 | ||
Director [Member] | |||
Unpaid Wages, Related Parties | $ 112,087 |
Note 10 - Sale of Membership _2
Note 10 - Sale of Membership Interests in GB Sciences Louisiana, LLC (Details Textual) - USD ($) | Oct. 29, 2020 | Sep. 30, 2020 | Aug. 24, 2020 | Aug. 04, 2020 | Nov. 15, 2019 | Feb. 12, 2018 | Oct. 15, 2020 | Mar. 31, 2020 | Sep. 30, 2020 | Aug. 23, 2020 |
John Davis [Member] | ||||||||||
Due to Related Parties, Total | $ 189,423 | |||||||||
Agreement With Louisiana State University AgCenter [Member] | ||||||||||
Annual Research Contributions | $ 250,000 | $ 250,000 | ||||||||
GB Sciences Louisiana, LLC [Member] | ||||||||||
Proceeds from Divestiture of Businesses | $ 8,000,000 | |||||||||
Earnout Payments | $ 8,000,000 | |||||||||
Proceeds from Collection of Notes Receivable | $ 500,000 | |||||||||
Notes Receivable, Net, Scheduled Payments | $ 500,000 | $ 750,000 | ||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,350,000 | $ 5,224,423 | $ 4,350,000 | |||||||
Gain (Loss) on Modification of Note Receivable | $ (1,895,434) | |||||||||
GB Sciences Louisiana, LLC [Member] | Subsequent Event [Member] | ||||||||||
Notes Receivable, Not Yet Collectible | $ 4,350,000 | |||||||||
Notes Receivable, Due Date Extended | 4,350,000 | |||||||||
Notes Receivable, Amount for Which Proof of Funds is Required | 4,350,000 | |||||||||
Notes Receivable, Escrow Deposit Required of Other Party | 250,000 | |||||||||
Notes Receivable, Escrow Payment Received | $ 250,000 | |||||||||
GB Sciences Louisiana, LLC [Member] | Forecast [Member] | ||||||||||
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness | 5,224,423 | |||||||||
Debt Instrument, Decrease, Forgiveness | 324,423 | |||||||||
Proceeds from Collection of Notes Receivable | 4,900,000 | |||||||||
Note Receivable Satisfied | 8,000,000 | |||||||||
Annual Research Contribution Commitment to LSU Assumed by Counter Party | $ 250,000 | |||||||||
Wellcana Group, LLC [Member] | ||||||||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 49.99% | |||||||||
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member] | ||||||||||
Sale of Stock, Percentage of Ownership | 50.01% | 15.00% | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 3,000,000 | $ 7,000,000 | ||||||||
Sale of Stock, Percentage of Ownership Available For Sale | 35.00% | |||||||||
Sale of Stock, Percentage of Available Stock For Sale, Percent to be Sold Per Transaction | 5.00% | |||||||||
Sale of Stock, Consideration Received Per Transaction | $ 1,000,000 |
Note 11 - Sale of Membership _2
Note 11 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual) | Mar. 24, 2020USD ($) | Nov. 27, 2019USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2020USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($) | Jul. 24, 2020USD ($) | Dec. 06, 2019USD ($) | Oct. 23, 2017 |
Proceeds from Lines of Credit, Total | $ 125,000 | ||||||||
Teco [Member] | |||||||||
Sale of Stock, Percentage of Ownership | 100.00% | ||||||||
Proceeds from Divestiture of Businesses | $ 4,000,000 | ||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | ||||||||
Notes Receivable, Interest Rate | 8.00% | ||||||||
Notes Receivable, Term of Monthly Installments (Month) | 3 years | ||||||||
Line of Credit [Member] | |||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | ||||||||
Proceeds from Lines of Credit, Total | $ 485,000 | ||||||||
Teco Note [Member] | Line of Credit [Member] | |||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 470,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||
The July 24 Note [Member] | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||
The July 24 Note [Member] | Teco [Member] | |||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | ||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | ||||||||
The July 24 Note [Member] | Secured Debt [Member] | AJE Management, LLC [Member] | |||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 500,000 | ||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | ||||||||
Proceeds from Lines of Credit, Total | $ 125,000 | ||||||||
July 24 Note [Member] | Teco [Member] | |||||||||
Financing Receivable, after Allowance for Credit Loss, Total | $ 4,000,000 | ||||||||
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding | 3 | ||||||||
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | |||||||||
Debt Instrument, Interest Rate, Stated Percentage | 0.00% | 0.00% | |||||||
Teco [Member] | |||||||||
Sale of Stock, Percentage of Ownership | 75.00% | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 3,000,000 | ||||||||
Sale of Stock, Additional Earn-out Payments | $ 3,000,000 | ||||||||
GB Sciences Nopah, LLC [Member] | |||||||||
Sale of Stock, Percentage of Ownership | 100.00% | ||||||||
Sale of Stock, Consideration Received on Transaction | $ 300,000 | ||||||||
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member] | |||||||||
Sale of Stock, Consideration to Be Received By Means of Debt Reduction | $ 300,000 |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) - USD ($) | Oct. 29, 2020 | Oct. 20, 2020 | Oct. 05, 2020 | Nov. 12, 2020 | Nov. 12, 2020 | Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Oct. 15, 2020 | Jul. 24, 2020 | May 07, 2020 |
Proceeds from Lines of Credit, Total | $ 125,000 | |||||||||||
The July 24 Note [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
The July 24 Note [Member] | Revolving Credit Facility [Member] | ||||||||||||
Proceeds from Lines of Credit, Total | $ 125,000 | |||||||||||
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member] | ||||||||||||
Repayments of Long-term Debt, Total | $ 8,000,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
Subsequent Event [Member] | ||||||||||||
Class of Warrant or Right, Exercised During Period (in shares) | 1,246,750 | |||||||||||
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share) | $ 0.03 | |||||||||||
Proceeds from Warrant Exercises, Net of Brokerage Fees | $ 33,663 | |||||||||||
Payments of Brokerage Fees in Connection With Warrants Exercised | $ 3,740 | |||||||||||
Subsequent Event [Member] | The July 24 Note [Member] | Revolving Credit Facility [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
Proceeds from Lines of Credit, Total | $ 75,000 | |||||||||||
Short-term Debt, Total | $ 200,000 | |||||||||||
Subsequent Event [Member] | Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member] | ||||||||||||
Repayments of Long-term Debt, Total | $ 150,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
Subsequent Event [Member] | GB Sciences Louisiana, LLC [Member] | ||||||||||||
Notes Receivable, Not Yet Collectible | $ 4,350,000 | |||||||||||
Notes Receivable, Due Date Extended | 4,350,000 | |||||||||||
Notes Receivable, Amount for Which Proof of Funds is Required | 4,350,000 | |||||||||||
Notes Receivable, Escrow Deposit Required of Other Party | $ 250,000 | |||||||||||
Notes Receivable, Escrow Payment Received | $ 250,000 |